Pfizer’s druglikeness criteria have expandedthe acceptable size range, having been developed to accommodate theemergence of novel hybrid drugs with unique characteristics advancinginto clinical phases.,, In this research, we developed a series of PROTACs and molecularglues or the targeted degradation of the RNA-binding protein HuR.Notably, several compounds from both classes significantly decreaseHuR levels and influence the cancer-associated phenotype in breastcancer cells. Here, ELAVL1 is linked to cancer.